{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:42:40Z","timestamp":1793353360005,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01266-1","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T11:05:24Z","timestamp":1726139124000},"page":"2771-2785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cutaneous Manifestations in Patients with Dermatomyositis, Are They Only Skin Deep?"],"prefix":"10.1007","volume":"14","author":[{"given":"Stephanie","family":"McKee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Xenakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Makin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Winnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"1266_CR1","unstructured":"UK M. Dermatomyositis 2023 [April 2024]; Available from: https:\/\/www.myositis.org.uk\/myositis-info\/conditions\/dermatomyositis\/."},{"issue":"11","key":"1266_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","volume":"7","author":"AB Robinson","year":"2011","unstructured":"Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7(11):664\u201375.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1266_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","volume":"54","author":"LHM Jennifer","year":"2006","unstructured":"Jennifer LHM, Christie LC, Wei L, Beverly S, Gil Y, Steven F, Joseph LJ. Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life. J Am Acad Dermatol. 2006;54(2):217\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"1266_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875492","volume":"9","author":"H Ujiie","year":"2022","unstructured":"Ujiie H, Rosmarin D, Sch\u00f6n MP, St\u00e4nder S, Boch K, Metz M, et al. Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Front Med (Lausanne). 2022;9: 875492.","journal-title":"Front Med (Lausanne)"},{"key":"1266_CR5","first-page":"9","volume":"9","author":"H Ujiie","year":"2022","unstructured":"Ujiie H, Rosmarin D, Schoen MP, Staender S, Boch K, Metz M, et al. Unmet medical needs in chronic non-communicable inflammatory skin diseases. Front Med-Lausanne. 2022;9:9.","journal-title":"Front Med-Lausanne"},{"issue":"4","key":"1266_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.18223","volume":"182","author":"S Ahmed","year":"2020","unstructured":"Ahmed S, Chakka S, Concha J, Krain R, Feng R, Werth VP. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. Br J Dermatol. 2020;182(4):949\u201354.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1266_CR7","first-page":"99","volume":"61","author":"SA Castro-Molina","year":"2023","unstructured":"Castro-Molina SA, M\u00e9ndez-Flores S. Anti-MDA5 dermatomyositis. Literature review. Rev Med Inst Mex Seguro Soc. 2023;61(1):99\u2013105.","journal-title":"Rev Med Inst Mex Seguro Soc"},{"issue":"5","key":"1266_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"AR Findlay","year":"2015","unstructured":"Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638\u201356.","journal-title":"Muscle Nerve"},{"key":"1266_CR9","unstructured":"The Myositis Association. Dermatomyositis. Available at: https:\/\/www.myositis.org\/about-myositis\/types-of-myositis\/dermatomyositis\/ (Accessed July 2023)."},{"key":"1266_CR10","unstructured":"Johns Hopkins Medicine. Dermatomyositis. Available at: https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/dermatomyositis#:~:text=Dermatoyositis%20is%20the%20term%20used,be%20diagnosed%20with%20the%20disease. (Accessed July 2023)."},{"issue":"12","key":"1266_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","volume":"134","author":"R Buchbinder","year":"2001","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087\u201395.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1266_CR12","first-page":"409","volume":"65","author":"T Hu","year":"2019","unstructured":"Hu T, Vinik O. Dermatomyositis and malignancy. Can Fam Physician. 2019;65(6):409\u201311.","journal-title":"Can Fam Physician"},{"key":"1266_CR13","doi-asserted-by":"publisher","first-page":"117954761985537","DOI":"10.1177\/1179547619855370","volume":"12","author":"J Okogbaa","year":"2019","unstructured":"Okogbaa J, Batiste L. Dermatomyositis: an acute flare and current treatments. Clin Med Insights Case Rep. 2019;12:1179547619855370.","journal-title":"Clin Med Insights Case Rep"},{"issue":"2","key":"1266_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","volume":"16","author":"JM Olazagasti","year":"2015","unstructured":"Olazagasti JM, Baez PJ, Wetter DA, Ernste FC. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol. 2015;16(2):89\u201398.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1266_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","volume":"36","author":"I Bogdanov","year":"2018","unstructured":"Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: current concepts. Clin Dermatol. 2018;36(4):450\u20138.","journal-title":"Clin Dermatol"},{"issue":"1","key":"1266_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40900-018-0129-8","volume":"4","author":"DE Rolfe","year":"2018","unstructured":"Rolfe DE, Ramsden VR, Banner D, Graham ID. Using qualitative Health Research methods to improve patient and public involvement and engagement in research. Res Involv Engag. 2018;4(1):49.","journal-title":"Res Involv Engag"},{"issue":"1","key":"1266_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12969-019-0332-7","volume":"17","author":"P Livermore","year":"2019","unstructured":"Livermore P, Gray S, Mulligan K, Stinson JN, Wedderburn LR, Gibson F. Being on the juvenile dermatomyositis rollercoaster: a qualitative study. Pediatr Rheumatol Online J. 2019;17(1):30.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1266_CR18","unstructured":"Food and Drug Administration (FDA). Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009."},{"key":"1266_CR19","unstructured":"Food and Drug Administration (FDA). Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2020."},{"key":"1266_CR20","unstructured":"Food and Drug Administration (FDA). Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Guidance for Industry (DRAFT), Food and Drug Administration Staff, and Other Stakeholders. 2022."},{"key":"1266_CR21","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: methods to identify what is important to patients. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2022."},{"key":"1266_CR22","unstructured":"Food and Drug Administration (FDA). Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making. Guidance for Industry (DRAFT). 2023."},{"issue":"9","key":"1266_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O'Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351.","journal-title":"Acad Med"},{"issue":"9","key":"1266_CR24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"1","key":"1266_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"9","key":"1266_CR26","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):1408\u201316.","journal-title":"Qual Rep"},{"issue":"2","key":"1266_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/acr.24786","volume":"75","author":"VL Kronzer","year":"2023","unstructured":"Kronzer VL, Kimbrough BA, Crowson CS, Davis JM III, Holmqvist M, Ernste FC. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res. 2023;75(2):348\u201355.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"1266_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME DeWane","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"1266_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Soc Sci Med. 2022;292: 114523.","journal-title":"Soc Sci Med"},{"key":"1266_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s41687-018-0060-7","volume":"2","author":"A Degboe","year":"2017","unstructured":"Degboe A, Knight SL, Halling K, Trigg A, Al-Zubeidi T, Aldhouse N, et al. Patients\u2019 experience of recurrent\/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study. J Patient Rep Outcomes. 2017;2:33.","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"1266_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.21037\/atm-20-5175","volume":"9","author":"LM Hodgkinson","year":"2021","unstructured":"Hodgkinson LM, Wu TT, Fiorentino DF. Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med. 2021;9(5):433.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1266_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3899\/jrheum.131247","volume":"41","author":"H Alexanderson","year":"2014","unstructured":"Alexanderson H, Grande MD, Iii COB, Orbai A-M, Sarver C, Clegg-Smith K, et al. Patient-reported outcomes and adult patients\u2019 disease experience in the idiopathic inflammatory myopathies report from the OMERACT 11 myositis special interest group. J Rheumatol. 2014;41(3):581\u201392.","journal-title":"J Rheumatol"},{"key":"1266_CR33","unstructured":"Christopher-Stine L, Ciesluk A, Chinoy H, Goyal NA, Gunter K, Isenberg D, et al. The dermatomyositis disease symptom questionnaire (DM-DSQ): a measure to assess the patient experience of dermatomyositis symptoms. J Rheumatol"},{"issue":"8","key":"1266_CR34","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00403-023-02625-2","volume":"315","author":"J Kleitsch","year":"2023","unstructured":"Kleitsch J, Weiner JD, Pandya R, Concha JS, Lim D, Werth VP. The physical and emotional impact of cutaneous dermatomyositis: a qualitative study. Arch Dermatol Res. 2023;315(8):2431\u20135.","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01266-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01266-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01266-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:21:16Z","timestamp":1729009276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01266-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01266-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Pfizer Inc., and Jason Xenakis is an employee of Pfizer Inc. Randall Winnette, who is currently employed by Novartis, was also an employee at Pfizer Inc. when this research was conducted. The authors indicated no further potential conflicts of interest. Randall Winnette is a current employee of Novartis. This research was conducted when Randall Winnette was an employee at Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical review of the patient interview part of this study was sought from the WCG IRB in the US. Approval date: 8 September 2021, IRB tracking number: 20214484, study number: 1316795. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Written informed consent was obtained from patients prior to their interview, and they were compensated for their time.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}